HBV reactivation is a common complication in HBsAg-positive and HBcAb-positive patients undergoing immunosuppressive anticancer therapy

Prophylactic therapy with nucleoside analogues has been shown to significantly decrease the incidence and morbidity of HBV reactivation

HBsAg positive patients should begin prophylactic antiviral therapy before chemotherapy and continue at least 3 months after the end of chemotherapy

For HBsAg-negative patients who have evidence of previous infection (HBcAb-positive), either prophylactic antiviral therapy or close monitoring with targeted therapy is suggested

HBV vaccination is recommended for all HBsAg-negative recipients prior to hematopoietic stem cell transplantation